Abstract
Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources, and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on pharmacogenomics implementation. Clinical workforce upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.
Original language | English |
---|---|
Journal | European Heart Journal - Cardiovascular Pharmacotherapy |
Volume | 8 |
Issue number | 1 |
Pages (from-to) | 100-103 |
Number of pages | 4 |
ISSN | 2055-6837 |
DOIs | |
Publication status | Published - 5 Jan 2022 |
Bibliographical note
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.Keywords
- Genetics
- Pharmacogenomics
- Pharmacotherapy
- Therapeutics